

# Health-Related Quality of Life in Adults With Classical Infratentorial Superficial Siderosis

## A Cross-sectional Study

Natallia Kharytaniuk, MRCS(ENT), MRCS(I), MCh, Amir Ala Mazaheri, MSc, Menelaos Pavlou, MSc, David J. Werring, FRCP, PhD, and Doris-Eva Bamiou, MD, MSc, FRCP, PhD

*Neurology*® 2022;99:e2201-e2211. doi:10.1212/WNL.000000000000201115

### Correspondence

Dr. Kharytaniuk  
n.kharytaniuk@ucl.ac.uk

## Abstract

### Background and Objectives

Infratentorial superficial siderosis (iSS) is a rare but disabling neurologic condition characterized by progressive hearing loss and balance and mobility problems. The functional decline in these neurologic domains with iSS progression is likely to adversely affect health-related quality of life (HRQoL). We studied the HRQoL of adults with iSS using 2 common generic HRQoL measures (Health Utilities Index Mark III [HUI3] and EuroQoL EQ5D [5 Level]) to determine the most affected domains and evaluate the association between HRQoL scores and disease duration.

### Methods

This observational study was an anonymous online survey. Following institutional Research Ethics Committee approval, we contacted dedicated international organizations, charities, and patient groups identified through online searches, social media, and collaborative networks, to distribute the study information and study link, inviting their members diagnosed with iSS to participate. Participation required access to a digital device connected to the Internet, confirmation of eligibility (aged 18 years and older and previously diagnosed with iSS), and informed consent to participate in the survey, which included study-specific questions (demographics, iSS, and hearing) and HRQoL questionnaires. Survey responses were captured by the Research Electronic Data Capture survey software and analyzed using the SPSS statistical package. Linear regression analysis was performed to investigate the association between HRQoL scores and disease duration.

### Results

Of 50 participants, 60% were male; the median (interquartile range [IQR]) age was 60 (15) years. The median (IQR) multiattribute scores for HUI3 and EQ5D were 0.36 (0.53) and 0.64 (0.33), respectively. The most frequently affected domains (moderate or worse category) were hearing (64%) and pain (48%) for HUI3 and mobility (54%) and pain (50%) for EQ5D. There was a weak association between disease duration and multiattribute scores for HUI3 ( $R = 0.353$ ; adjusted  $R^2 = 0.096$ ;  $b = -0.008$ ;  $p = 0.047$ ) but not EQ5D.

### Discussion

Our findings demonstrate low HRQoL scores that capture low functional status in several domains typically affected in iSS, suggesting that iSS has a major adverse effect on quality of life in multiple functional domains. Measures of HRQoL in iSS should be included in clinical and research settings, including treatment trials.

From the Ear Institute (N.K., D.-E.B.), Stroke Research Centre (D.W.), Department of Brain Repair and Rehabilitation, Queen Square Institute of Neurology (A.A.M.), and Department of Statistical Science (M.P.), University College London; and National Institute for Health and Care Research (N.K., D.-E.B.), University College London Hospitals Biomedical Research Centre (Deafness and Hearing Problems Theme), London; Southampton School of Medicine (A.A.M.), University of Southampton, UK.

Go to [Neurology.org/N](https://www.neurology.org/N) for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

The Article Processing Charge was funded by the transformative agreement with University College London.

This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

## Glossary

**EQ5D** = EuroQOL-5D; **HRQoL** = health-related quality of life; **HUI3** = Health Utilities Index Mark III; **IQRs** = interquartile ranges; **iSS** = infratentorial superficial siderosis; **NICE** = National Institute for Health and Care Excellence; **REDCap** = Research Electronic Data Capture; **VAS** = visual analog scale.

Classical infratentorial superficial siderosis (iSS) of the CNS is a rare but disabling neurologic disorder that is associated almost invariably with hearing loss and often imbalance (ataxia) and myelopathy.<sup>1</sup> Other features of iSS, which are probably underreported, include cognitive impairment, bladder and bowel dysfunction, and chronic pain.<sup>1-3</sup>

iSS is characterized by slow low-volume bleeding into the CSF—in most cases due to a dural defect caused by CNS trauma or surgery—which leads to hemoglobin breakdown and the generation of toxic iron species that are bound to ferritin forming hemosiderin deposits on the surfaces of the CNS structures including the cerebellum, brainstem, craniocervical junction, and spinal cord<sup>2</sup> (Figure 1). Although the clinical course is highly variable, there is often progressive functional decline, with deterioration in hearing, balance, and mobility, and other symptoms.<sup>1-5</sup> Treatment is predominantly aimed at identifying and repairing the source of bleeding, halting the effect of neurotoxic iron with an iron-chelating agent (e.g., deferiprone), or both.<sup>2,6,7</sup>

iSS is considered rare (defined as 1 per 2,000 EU population or affecting less than 200,000 individuals in the USA).<sup>8-11</sup> The


prevalence of iSS is not well described, but a few studies indicate this to be between 0.03% and 0.14%, which may be similar to that of other progressive neurodegenerative disorders such as Friedreich ataxia and some subtypes of spinocerebellar ataxia.<sup>12-18</sup>

The importance of evaluating the individual's perspectives of living with a rare disorder and assessing its effect on daily functioning has been previously highlighted, with measurement of quality of life suggested as a particular priority for research in rare disorders.<sup>19-22</sup>

The gradual functional decline in iSS, likely with disease progression, and involvement of multiple functional domains may have a marked negative impact on (health-related) quality of life (HRQoL) of individuals with iSS. Thus, an understanding of HRQoL is critical to understanding the true health effect of iSS.

Although the terms QoL and HRQoL have been used interchangeably, in this study, we used the term HRQoL defined by the UK's National Institute for Health and Care Excellence (NICE) as “a combination of a person's overall

**Figure 1** Axial Magnetic Resonance Images Showing Typical Appearances of Hemosiderin in iSS



T2-weighted (A, C) and corresponding paramagnetic (B, D) sequences; images demonstrate the involvement of infratentorial regions: superior vermis (arrowheads, A, B), cerebellar folia (solid arrows, C, D), and midbrain (dashed arrows, A–D).

physical, mental and social wellbeing, not merely the absence of disease.<sup>23,24</sup> To measure HRQoL, they recommend using EQ5D—a generic HRQoL instrument, commonly used for benchmarking in the National Health Service.<sup>25,26</sup> However, NICE also recognize the need for disease-specific or other generic instruments that capture key domains specific for the disease of interest.<sup>27</sup>

To the best of our knowledge, the effect of iSS on HRQoL has not been systematically studied, and no dedicated HRQoL measures for iSS exist. The aims of this study were as follows: to calculate the overall HRQoL multiattribute scores of the individuals with iSS using 2 common generic HRQoL instruments; to determine which domains demonstrate the lowest (worst affected) functional status for each instrument; and to evaluate for the association between HRQoL scores and disease duration.

## Methods

### Study Design and Setting

This observational study was an anonymous online survey that included study-specific questions and 2 validated generic HRQoL questionnaires, administered using the institution-licensed Research Electronic Data Capture (REDCap) survey platform. The online format was chosen to allow participation of individuals in a range of near and remote geographic locations and to overcome restrictions in place due to COVID-19.<sup>28,29</sup>

### Standard Protocol Approvals, Registrations, and Patient Consents

The study received approval by the University College London Research Ethics Committee (registration number: UCL REC 17413/001). Permissions for the academic use of the questionnaires were obtained from the EuroQOL Group for EQ5D (5-Level, English language [UK], self-administered REDCap [online] version, Registration ID 33674) and from HUInc, (Dundas, Ontario, Canada) for HUI3 (English language, self-administered, 1-week recall version).

Following the Research Ethics Committee approval, we contacted dedicated organizations, charities, and patient groups within and outside the UK, identified through online search, social media, and collaborative networks, to disseminate information about the survey and to invite their members who had been diagnosed with iSS to participate in the study. The information included a brief description of the study, a recruitment poster and participant information sheet, and the link to the study with the study-specific code.

Individuals interested in the study needed to have access to a digital device connected to the Internet to obtain information about the study and to access the study webpages. The first page contained a brief description of the study, the same participant information sheet distributed to the dedicated organizations and patient groups, and the description of the study inclusion criteria. Before commencing the survey,

potential participants were asked to confirm that they had read the study information sheet and were eligible for the study: that they were aged 18 years or older and had been diagnosed with superficial siderosis by a medical professional. The term “superficial siderosis” was defined as “superficial siderosis (infratentorial) of the CNS” and described in lay language as “a very rare neurologic condition characterized by a trickle of blood through a defect in the sheath that covers the brain or spinal cord and deposition of iron on the surface of the brain, brain-related structures, and/or spinal cord, in which hearing is most often involved.”

Potential participants were provided with the online consent form and were required to agree to all sections of the consent form by ticking all the boxes. Only then were they able to proceed to the survey webpages. The survey was open and active between April 2020 and July 2021.

### Survey Contents and Participation Process

After providing the consent, the participants were taken to the study pages that included study-specific questions and the questionnaires and were able to complete the survey at their own pace including pausing the survey if necessary.

### Study-Specific Questions

The survey-specific questions included participants' demographics (age, gender, and country of residence), iSS-specific questions (confirmation of diagnosis of iSS, age at diagnosis, whether causative event known, age at causative event, treatment, and year when commenced), and hearing-specific questions (if hearing difficulties in background noise and overall, and tinnitus present, age at onset of hearing problems, and otological history).

### HRQoL Questionnaires

Two generic HRQoL questionnaires were included in the study. First, the Health Utilities Index Mark III (HUI3) was chosen because it includes several domains that can be affected in individuals with iSS and has been identified as a better instrument to reflect HRQoL in persons with hearing complaints.<sup>1,30,31</sup> Second, the EuroQOL-5D (EQ5D) 5-level was chosen because it has been widely used in the UK in a variety of settings, although it includes fewer domains with limited coverage of those likely to be affected in iSS.<sup>32</sup> Both instruments provide multiattribute (utility) scores, representing overall health states, and are known to correlate with each other (Pearson  $r = 0.7$ ) including in a cohort with hearing impairment.<sup>31,33</sup>

The HUI3 and EQ5D questionnaires were presented to the participants in a fixed order. The HUI3 questionnaire includes 8 domains (attributes) and consists of 15 questions of 5–6 levels, which are converted into disability categories and utility scores.<sup>30,34</sup> The HUI3 domains and levels include (from Horsman et al.<sup>34</sup>):

1. Vision: from “able to see well enough to read ordinary newsprint and recognize a friend on the other side of the street, without glasses or contact lenses” (level 1) to “unable to see at all” (level 6);

2. Hearing: from “able to hear what is said in a group conversation with at least 3 other people, without a hearing aid” (level 1) to “unable to hear at all” (level 6);
3. Speech: from “able to be understood completely when speaking with strangers or friends” (level 1) to “unable to be understood when speaking to other people (or unable to speak at all)” (level 5);
4. Ambulation: from “able to walk around the neighbourhood without difficulty, and without walking equipment” (level 1) to “cannot walk at all” (level 6);
5. Dexterity: from “full use of 2 hands and 10 fingers” (level 1) to “limitations in use of hands or fingers, requires the help of another person for all tasks (not independent even with use of special tools)” (level 6);
6. Emotion: from “happy and interested in life” (level 1) to “so unhappy that life is not worthwhile” (level 5);
7. Cognition: from “able to remember most things, think clearly and solve day to day problems” (level 1) to “unable to remember anything at all, and unable to think or solve day to day problems” (level 6);
8. Pain: from “free of pain and discomfort” (level 1) to “severe pain that prevents most activities” (level 5);

The HUI3 outputs included the following: (1) single-attribute disability categories and utility scores and (2) multiattribute disability categories and utility scores. The scores' range of values was from 0.00 to 1.00 for single attributes (from the worst to perfect functional state), whereas the range of values for multiattribute scores, representing the overall HRQoL states, was from -0.36 to 1, with 0 equal to “being dead,” 1 being “perfectly healthy,” and less than zero scores representing “worse than dead” states.<sup>30</sup> Score differences of  $\geq 0.03$  were considered clinically significant.<sup>34</sup>

EQ5D (5-level) assesses HRQoL in 5 domains (dimensions) and in 5 categories (levels), which include (from Herdman et al.<sup>35</sup>) the following:

1. Mobility: from “I have no problems in walking about” (level 1) to “I am unable to walk about” (level 5);
2. Self-care: from “I have no problems washing or dressing myself” (level 1) to “I am unable to wash or dress myself” (level 5);
3. Usual activities: from “I have no problems doing my usual activities” (level 1) to “I am unable to do my usual activities” (level 5);
4. Pain/discomfort: from “I have no pain or discomfort” (level 1) to “I have extreme pain or discomfort” (level 5);
5. Anxiety/depression: from “I am not anxious or depressed” (level 1) to “I am extremely anxious or depressed” (level 5);

Each domain is represented by a number corresponding to the category of the perceived problem, and a unique health state can be derived from combinations of the categories and the domains. Other EQ5D outcome measures include respondents' self-perceived health states represented using visual analog scale

(VAS) provided by each participant as a number ranging from 0 to 100 (worst to best imaginable health state), and multiattribute (utility) scores derived using a country-specific value set reflecting the country-specific differences in values attributed to the health states.<sup>25</sup> The UK tariff (crosswalk model from EQ5D 3-level) was used to calculate the utility scores for all participants irrespective of their country of residence.<sup>36-38</sup> This was performed because a larger proportion of participants indicated the UK as their country of residence (followed by the USA). Participants' responses could not be standardized for demographic and geographic differences. The range of the UK tariff values was from -0.594 to 1.<sup>37,39</sup> The US tariff (value range from -0.109 to 1) was included for comparative purposes only.<sup>40,41</sup> The scores of 0 and 1 equalled to “being dead” and “perfectly healthy,” respectively, and “worse than dead” states were represented by less than zero scores.

## Data Collection

The data collected included coded answers to the study-specific questions and to the questionnaires. The study data were anonymous at the outset; therefore, no personally identifiable information was collected. Incomplete and duplicate entries were excluded from the analysis and not reported.

## Data Availability

Fully anonymized data will be available from the institution's research data repository ([doi.org/10.5522/04/19846924](https://doi.org/10.5522/04/19846924)) and will be stored for the duration stipulated by the institution's research data storage policy.

## Statistical Analysis

Statistical analysis was performed using SPSS version 27 (IBM Corp., Armonk, NY). A coded SPSS file with the study data outputs was generated by REDCap following the study closure. Participants' characteristics were summarized using descriptive statistics. Frequencies and percentages were reported for categorical data. All measures were assessed for normality using the Shapiro-Wilk test ( $p$  values  $>0.05$  confirming assumptions of normal distribution). The mean scores with SD were reported for continuous data with normal distribution; the median scores with interquartile ranges (IQRs) were reported for continuous data that seemed to deviate from normality.

Nonparametric tests were used for the analysis of data that seemed to violate assumptions of normal distribution. The Mann-Whitney  $U$  test was performed to assess the difference in the mean ranks of the utility scores based on gender, treatment status, the presence of hearing problems and tinnitus and between the multiattribute scores of EQ5D and HUI3. The significance level was set at 0.05.

Linear regression analysis was performed to study the associations between the instruments' scores and disease duration. Although the outcomes (EQ5D scores and calculated disease duration) exhibited slight skewness, the residuals from the model fits were assessed for normal distribution using histograms and probability (P-P) plots. There were no missing data within the HRQoL instruments.



## Results

### Demographics and Study-Specific Questions

Of 50 participants included in the study, 60% were male; the median age was 60 (IQR 15) years. Most participants (64%) reported the UK as their country of residence, followed by the USA (32%). English was the primary language for most (98%) (Table 1).

The likely causative event for developing iSS was known in 64% of cases; the mean age during the presumed causal event was 30 (SD 19), with 2 participants being younger than 1 year during the presumed event (Table 1).

The mean age during iSS diagnosis was 53 (SD 13) years. The median duration between the likely causative event and the diagnosis was 17 (IQR 24) years. In only 6% of

**Table 1** Participants' Demographics and iSS-Related and Hearing-Specific Characteristics

Parameters (n = 50)		Values (n, %)				
<b>Gender</b>						
Males		30 (60)				
Females		20 (40)				
<b>Country of residence</b>						
UK		32 (64)				
USA		16 (32)				
Other		2 (4)				
<b>Likely causative event known</b>						
Yes		32 (64)				
No		18 (36)				
<b>Age (y)</b>	<b>Mean</b>	<b>Median</b>	<b>SD</b>	<b>95% CI</b>	<b>IQR</b>	<b>Min-max</b>
At survey <sup>a</sup>	57.5	59.5	11.9	54.1–60.9	15.0	29–76
At diagnosis	52.8	54.5	12.6	49.2–56.4	18.0	21–73
At onset of hearing problems (n = 45) <sup>a,b</sup>	44.8	47.0	16.5	39.8–49.7	21.0	0–73
At causative event (n = 32)	30.0	30.0	19.2	23.1–36.9	29.0	0–66
<b>Time interval (y) from</b>	<b>Mean</b>	<b>Median</b>	<b>SD</b>	<b>95% CI</b>	<b>IQR</b>	<b>Min-max</b>
Causative event to survey (n = 32) <sup>a</sup>	25.6	20.5	14.2	20.5–30.7	28.0	7–54
Causative event to diagnosis (n = 32) <sup>a</sup>	19.9	16.5	13.9	14.9–24.9	23.8	0–48
Causative event to hearing symptoms (n = 30) <sup>a,b</sup>	10.0	12.0	20.0	2.6–17.5	17.0	–56–36
Onset hearing symptoms to diagnosis (n = 45) <sup>a,b</sup>	9.1	4.0	14.8	4.7–13.5	11.0	–3–66
Diagnosis to survey (n = 50) <sup>a</sup>	4.7	3.0	3.5	3.7–5.7	6.0	0–13
<b>Treatment</b>	Yes 28 (56%)	No 22 (44%)	—	—	—	—
Medication	21 (75%)	—	—	—	—	—
Surgery	3 (11%)	—	—	—	—	—
Both	4 (14%)	—	—	—	—	—
<b>Treatment duration, including since surgery (y, n = 26)<sup>a,b</sup></b>	3.8	3.0	3.4	2.4–5.2	6.0	0–12
<b>Hearing difficulties (overall)</b>	Yes 47 (94%)	No 3 (6%)	—	—	—	—
Difficulties in background noise	47 (100%)	n/a	—	—	—	—
<b>Tinnitus</b>	Yes 39 (78%)	No 11 (22%)	—	—	—	—

Abbreviations: IQR = interquartile range; n/a = not applicable.

<sup>a</sup> Seemed to violate assumption of normal distribution (Shapiro-Wilks test of normality,  $p < 0.05$ ).

<sup>b</sup> Not stated in 2 cases.

cases, the diagnosis was achieved within the same year of the likely causative event.

Most (94%) participants reported hearing difficulties, including in the presence of background noise (Table 1). The median age at the onset of hearing problems was 47 (IQR 21) years. A family history of early-onset hearing loss (not related to age) was reported by 14% participants. The median time interval between the onset of hearing symptoms and the diagnosis was 4 (IQR 11) years; 12% participants had the onset of hearing problems after the diagnosis (all within 3 years), and 10% participants reported the onset of hearing problems within the same year as diagnosis. The median time interval between the likely causative event and the onset of hearing symptoms was 12 (IQR 17) years, but some

hearing symptoms preceded the likely causative event in 12% of cases.


More than half (56%) of participants reported they had received treatment for iSS, 75% of whom were receiving medical treatment; 14% participants had received both surgery and medication. The mean treatment duration at the study participation was 4 (SD 3) years.

## HRQoL Measures

### HUI3

The most frequently affected domains (moderate or worse category) were hearing (64%), pain (48%), cognition (46%), and ambulation (42%) (Figure 2, Table 2). These domains

**Figure 2** Single Attributes by Categories for Both Instruments



A) Health Utilities Index Mark III (HUI3) and (B) EuroQOL-5D 5-level (EQ5D-5L).

**Table 2** Results for Health Utilities Index Mark III

HUI3 single attributes (n = 50)	Categories (functional levels) (n, %)				Scores
	None	Mild	Moderate	Severe	Mean, median, SD, 95% CI, IQR, min-max
Vision <sup>a</sup>	10 (20)	34 (68)	3 (6)	3 (6)	0.91; 0.95; 0.16; 0.86–0.95; 0.0; 0.38–1.0
Hearing <sup>a</sup>	11 (22)	7 (14)	18 (36)	14 (28)	0.58; 0.71; 0.36; 0.48–0.68; 0.54; 0.0–1.0
Speech <sup>a</sup>	37 (74)	4 (8)	9 (18)	0	0.92; 1.0; 0.16; 0.87–0.96; 0.18; 0.41–1.0
Cognition <sup>a</sup>	15 (30)	12 (24)	15 (30)	8 (16)	0.78; 0.92; 0.24; 0.71–0.85; 0.30; 0.32–1.0
Ambulation <sup>a</sup>	16 (32)	13 (26)	10 (20)	11 (22)	0.74; 0.83; 0.26; 0.67–0.81; 0.33; 0.16–1.0
Dexterity <sup>a</sup>	32 (64)	10 (20)	3 (6)	5 (10)	0.90; 1.0; 0.17; 0.86–0.95; 0.12; 0.45–1.0
Emotion <sup>a</sup>	16 (32)	21 (42)	10 (20)	3 (6)	0.86; 0.91; 0.19; 0.81–0.92; 0.27; 0.0–1.0
Pain <sup>a</sup>	10 (20)	16 (32)	17 (34)	7 (14)	0.82; 0.92; 0.17; 0.78–0.87; 0.15; 0.48–1.0
<b>Overall health state (multiattribute) measures</b>					
By levels	1 (2)	2 (4)	5 (10)	42 (84)	N/A
Index values (multiattribute scores)	0.36; 0.36; 0.33; 0.27–0.45; 0.53; –0.23–1.00				
Population norms for USA <sup>b</sup> (mean for 46–64 and 65+ age groups)	0.78; 0.70				
<b>Self-reported overall health status (levels) (n = 50)</b>					
Level n (%)	Excellent	V. good	Good	Fair	Poor
	2 (4)	13 (26)	18 (36)	11 (22)	6 (12)

Abbreviations: HUI3 = Health Utilities Index Mark III; IQR = interquartile range; N/A = not available; V. good = very good.

<sup>a</sup> Seemed to violate the assumption of normal distribution (the Shapiro-Wilk test of normality  $p < 0.05$ ).

<sup>b</sup> from Luo et al.<sup>42</sup>.

also demonstrated the lowest single-attribute scores (median, IQR): hearing (0.71, 0.54) and ambulation (0.83, 0.33), followed by cognition (0.92, 0.30) and pain (0.92, 0.15). Less frequently involved domains were emotion (26%), speech (18%), dexterity (16%), and vision (12%).

The mean HUI3 multiattribute scores were 0.36 (SD 0.33); scores less than zero were observed in 16% of cases; the highest score of 1 was reached in 2% of cases. The mean rank comparison (the Mann-Whitney *U* test) of HUI3 multiattribute scores identified statistically significant lower scores for female individuals ( $n = 20$ ;  $U = 196.0$ ;  $z = -2.06$ ;  $p = 0.039$ ) and for individuals with hearing problems ( $n = 47$ ;  $U = 138.0$ ;  $z = 2.76$ ;  $p = 0.006$ ), but not based on treatment status ( $n = 28$ ;  $U = 308.0$ ;  $z = 0.0$ ;  $p = 1.000$ ) or the presence of tinnitus ( $n = 39$ ;  $U = 141.0$ ;  $z = -1.72$ ;  $p = 0.085$ ).

### EQ5D

Analysis of the EQ5D categories (ranging from no problems to extreme problems) demonstrated that the most affected domains (moderate or worse category) were mobility (54%), pain (50%), and usual activities (40%); the least affected domain was self-care (16%) (Figure 2, Table 3).

The median values for the EQ5D multiattribute scores were 0.64 (IQR 0.33) and for the VAS were 60 (IQR 40); scores

less than zero were observed in 4% participants; the highest score of 1 was observed in 6% participants.

The mean rank comparison (the Mann-Whitney *U* test) of EQ5D multiattribute scores identified statistically significant lower scores for individuals with hearing problems ( $n = 47$ ;  $U = 122.0$ ;  $z = 2.10$ ;  $p = 0.035$ ) and those with tinnitus ( $n = 39$ ;  $U = 76.5$ ;  $z = -3.23$ ;  $p = 0.001$ ), but not based on gender ( $n = 20$ ;  $U = 201.5$ ;  $z = -1.95$ ;  $p = 0.051$ ) or treatment status ( $n = 28$ ;  $U = 352.0$ ;  $z = 0.86$ ;  $p = 0.39$ ).

### Analysis of HRQoL Scores and Disease Duration

The multiattribute scores for HUI3 (mean rank = 39.9) seemed to be lower than the EQ5D multiattribute scores (mean rank = 61.1); the difference was statistically significant:  $U = 1778.5$ ,  $z = 3.64$ ;  $p < 0.001$ .

Linear regression analysis identified a strong association between both instruments' multiattribute scores despite the statistically significant difference in their mean ranks:  $R = 0.635$ ; adjusted  $R^2 = 0.391$ ;  $b = 0.503$ ; 95% CI 0.325–0.680; and between the HUI3 multiattribute scores and EQ5D VAS values:  $R = 0.665$ ; adjusted  $R^2 = 0.430$ ;  $b = 0.009$ ; 95% CI 0.006–0.012 (Table 4).

There was a weak association between disease duration and multiattribute scores for HUI3 ( $R = 0.353$ ; adjusted  $R^2 = 0.096$ ;

**Table 3** Results for EuroQOL-5D 5-Level

EQ5D dimensions (n = 50)	Categories (levels) (n, %)					Normative values <sup>a</sup>	
	No problems	Slight problems	Moderate problems	Severe problems	Extreme problems (unable to)	Percentage of any problems reported by 5 dimensions, UK (USA)	
<b>Mobility</b>	9 (18)	14 (28)	15 (30)	10 (20)	2 (4)	18.4 (18.5)	
<b>Self-care</b>	29 (58)	13 (26)	6 (12)	1 (2)	1 (2)	4.3 (3.7)	
<b>Usual activities</b>	11 (22)	19 (38)	13 (26)	5 (10)	2 (4)	16.3 (17.9)	
<b>Pain</b>	8 (16)	17 (34)	19 (38)	5 (10)	1 (2)	33.0 (48.3)	
<b>Anxiety/depression</b>	23 (46)	15 (30)	8 (16)	3 (6)	1 (2)	21.0 (23.2)	
	<b>Study cohort (mean; median; SD; 95% CI; IQR; min-max)</b>					<b>Normative data (mean, SD, 95% CI)</b>	
<b>VAS<sup>b,c</sup></b>	59.5; 60.0; 23.5; 52.9–66.2; 40.0; 17–95					UK	81.4; 5.1; 76.0–86.7
						USA	77.5; 5.4; 71.9–83.1
<b>Multiatribute (utility) scores<sup>b</sup></b>	UK 0.59; 0.64; 0.26; 0.51–0.66; 0.33; –0.22 – 1.00					UK	0.83; 0.08; 0.75–0.91
	USA 0.69; 0.74; 0.18; 0.64–0.74; 0.22; 0.15–1.00					USA	0.84; 0.06; 0.78–0.90

Abbreviations: EQ5D = EuroQOL-5D; IQR = interquartile range; VAS = visual analog scale.

<sup>a</sup> Unstandardized normative values (age-specific to match the study cohort), from Szende et al.<sup>41</sup>

<sup>b</sup> Seemed to violate assumption of normal distribution (the Shapiro-Wilk test of normality,  $p < 0.05$ ).

<sup>c</sup> Scores 0–100 representing worst-best possible health states.<sup>41</sup>

$b = -0.008$ ; 95% CI  $-0.016$  to  $-0.000102$ ) but not EQ5D (Table 4). Although the EQ5D scores and disease duration demonstrated slightly skewed data distribution, the residuals from the linear regression model fits demonstrated approximately normal distribution (assessed using histograms and probability [P-P] plots).

## Discussion

To the best of our knowledge, this is the first study to quantitatively and systematically capture HRQoL in iSS. Using 2 common validated generic measures (HUI3 and EQ5D), we found that HRQoL scores were lower than population norms for both instruments (Figure 3, Tables 2 and 3).<sup>41–43</sup> HUI3 identified moderate or worse overall functional status in 94% of participants. Hearing difficulty is the most frequently reported feature of iSS, which was observed in our study, with the worst functional levels and utility scores observed in the HUI3 hearing domain.

The study findings also demonstrated the effect of iSS on multiple functional domains including hearing, cognition, ambulation, and pain, all of which have been reported as being affected in patients with iSS.<sup>1–3</sup> These findings suggest that pain and cognitive impairment in iSS may have a similar prevalence as problems with mobility and hearing, so may be key aspects of the iSS clinical syndrome. Indeed, cognitive impairment has been observed in 50% of patients with iSS studied in the clinical setting.<sup>3</sup>

EQ5D analysis identified mobility and pain as the most frequently affected domains, in keeping with the HUI3 affected

domains of ambulation and pain. However, the EQ5D may underestimate the effect of iSS on HRQoL for individuals in whom hearing or cognitive problems predominate because these domains are not included in the EQ5D. Thus, in the absence of iSS-specific measures, HUI3 might be a more suitable instrument for assessing HRQoL in adults with iSS, in line with the NICE recommendations for tailored HRQoL instruments.<sup>27</sup>

Furthermore, the HUI3's potentially superior sensitivity to measure HRQoL in iSS is probably also reflected in the instruments' multiatribute scores that were significantly lower than for EQ5D. More HUI3 multiatribute scores were observed to be less than zero than for EQ5D; however, this might be due to the previously described floor and ceiling effects.<sup>33,44</sup>

The multiatribute scores seemed to be worse for participants with hearing problems (for both EQ5D and HUI3) and with tinnitus (for EQ5D). It possible that despite not including hearing as a domain, the EQ5D anxiety/depression domain was partially able to capture the effect of tinnitus on HRQoL because it is well known to be related to anxiety and stress.

The scores observed in our cohort seemed to be similar to those derived from patients with several other complex neurologic conditions, such as patients with moderate disability from traumatic brain injury (mean scores of 0.51 [EQ5D, Dutch tariff] and HUI3 0.48 for moderate and 0.33 lower moderate disability), although direct comparisons between the studies could not be made due to demographic differences (age, country of study, and tariffs used) and the severity of disorders for which HUI3 and EQ5D were reported.<sup>45</sup> The



**Table 4** Linear Regression Analysis Between the Instruments' Scores and Disease Duration

	R Coeff	Adj R <sup>2</sup>	b-coeff	95% CI	p Value
<b>HUI3 multiattribute scores (n = 50)</b>					
EQ5D multiattribute scores (UK tariff)	0.635	0.391	0.503	0.325 to 0.680	<0.001
EQ5D (VAS)	0.665	0.430	0.009	0.006 to 0.012	<0.001
<b>Disease duration (n = 32)</b>					
HUI3 multiattribute scores	0.353	0.096	-0.008	-0.016 to -0.000102	0.047
EQ5D multiattribute scores (UK tariff)	0.302	0.061	-0.006	-0.013 to 0.001	0.093
EQ5D VAS	0.094	-0.024	-0.156	-0.773 to 0.461	0.610

Abbreviations: Adj adjusted; EQ5D = EuroQOL-5D; HUI3 = Health Utilities Index Mark III; VAS = visual analog scale. Disease duration was calculated from the likely causative event to the survey; level of significance was set at 0.05; asymptotic 2-tailed *p*-values provided.

mean EQ5D multiattribute scores (and VAS values) in our study also seemed to be similar to those reported for motor neuron disease: 0.57 (60) (albeit in an older cohort),<sup>46</sup> and in stroke patients of similar age: 0.52 (53).<sup>37</sup>

The strength of this study is that it is first of its kind to measure HRQoL in iSS. The anonymous online format facilitated reaching out to wider patient population groups and optimizing recruitment opportunities. This approach may also have reduced bias associated with face-to-face completion of questionnaires.<sup>47</sup> The sample size in our study should be considered as large in view of iSS rarity because most of studies' cohorts with iSS are in single or teen figures.

There are several limitations to our study. We were unable to independently verify the clinical and radiologic diagnosis of iSS, including brain and spine MRI. To mitigate this, participants were asked twice to confirm their diagnosis: first, in the consent form and then, again within the study-specific

questions. Participants needed to have access to a digital device and Internet, which might have introduced selection bias, whereas order bias may have resulted from presentation of questionnaires in a fixed order and recall bias due to the retrospective nature of study specific questions. The study was conducted predominantly focusing on problems with hearing because it is often the most common and earliest symptom reported by individuals with iSS; we did not collect data on urinary and bowel problems, and they are likely not to have been captured by the 2 instruments used in the study.


Although our results demonstrated the presence of association between the HUI3 multiattribute scores and disease duration, this analysis should be interpreted with caution because the self-perceived HRQoL may be influenced by other factors, which might not have been accounted for in this study—including the individual's coping strategies and abilities.

Owing to the study design, the collected outcomes could not be compared with objective clinical measures of impairments reflecting the severity of iSS clinical syndrome. Further longitudinal studies are needed to correlate HRQoL utility scores with clinical measures and determine whether HUI3 can capture small but clinically significant changes over time.

This study found markedly reduced HRQoL scores in iSS, which may be comparable with other complex neurologic conditions, highlighting an unmet need for health care resources to tackle the consequences of iSS. Our study identified potential advantages of HUI3 over EQ5D in iSS including assessment of hearing, lower multiattribute scores, and correlation of HUI3 scores with disease duration (suggesting face validity). Because iSS-specific HRQoL measures are lacking, we therefore propose the use of HUI3 (or a combination of HUI3 and EQ5D) to capture the effect of iSS on HRQoL.

### Acknowledgment

The authors are grateful to the dedicated patient groups, charities, and organizations that helped distribute the study information. The authors extend their gratitude to all study

**Figure 3** EuroQOL-5d (EQ5D) Visual Analogue Scale (VAS) Values for the UK and the USA Cohorts

Respective country norms provided from Janssen et al.<sup>38</sup>

participants for their interest and time completing our survey. The authors also thank the HUInc. and EuroQoL teams for their professional and expedient services and support.

## Study Funding

The research costs were supported in part by the NIHR UCLH BRC Deafness and Hearing Problems Theme (BRC-1215-20016-546624) and by the Health Utilities Inc. grant (license fee waiver). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.

## Disclosure

The work performed by N. Kharytaniuk was funded by the NIHR UCLH BRC Deafness and Hearing Problems Theme (doctoral studentship grant BRC-1215-20016-546624-175870). A.A. Maza-heri, M. Pavlou, and D.J. Werring report no disclosures relevant to the manuscript. D.E. Bamioú's time for this manuscript was funded by the NIHR UCLH BRC Deafness and Hearing Problems Theme. Go to [Neurology.org/N](http://Neurology.org/N) for full disclosures.

## Publication History

Received by *Neurology* February 23, 2022. Accepted in final form June 30, 2022. Submitted and externally peer reviewed. The handling editor was José Merino, MD, MPhil, FAAN.

## Appendix Authors

Name	Location	Contribution
<b>Natallia Kharytaniuk, MRCS(ENT) MRCS(I), MCh</b>	Ear Institute, University College London, UK; National Institute for Health and Care Research, University College London Hospitals Biomedical Research Centre (Deafness and Hearing Problems Theme), London, UK	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: the study was conceptualized by DEB, DJW, NK, and AAM. Pilot findings from the study were included in the AAM's MSc Thesis. NK prepared the first draft of this article. MP provided guidance regarding statistical analysis. All authors reviewed the article for intellectual content, provided comments, and edited and reviewed the final version of the article
<b>Amir Ala Mazaheri, MSc</b>	Queen Square Institute of Neurology, University College London, UK; Southampton School of Medicine, University of Southampton, UK	Drafting/revision of the article for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: the study was conceptualized by DEB, DJW, NK, and AAM. Pilot findings from the study were included in the AAM's MSc Thesis. NK prepared the first draft of this article. MP provided guidance regarding statistical analysis. All authors reviewed the article for intellectual content, provided comments, edited, and reviewed the final version of the article

## Appendix (continued)

Name	Location	Contribution
<b>Menelaos Pavlou, MSc</b>	Department of Statistical Science, University College London, UK	Drafting/revision of the article for content, including medical writing for content; analysis or interpretation of data; additional contributions: the study was conceptualized by DEB, DJW, NK, and AAM. Pilot findings from the study were included in the AAM's MSc Thesis. NK prepared the first draft of this article. MP provided guidance regarding statistical analysis. All authors reviewed the article for intellectual content, provided comments, and edited and reviewed the final version of the article
<b>David J. Werring, FRCP, PhD</b>	Stroke Research Centre, Department of Brain Repair and Rehabilitation, Queen Square Institute of Neurology, University College London, UK	Drafting/revision of the article for content, including medical writing for content; study concept or design; analysis or interpretation of data; additional contributions: the study was conceptualized by DEB, DJW, NK, and AAM. Pilot findings from the study were included in the AAM's MSc Thesis. NK prepared the first draft of this article. MP provided guidance regarding statistical analysis. All authors reviewed the article for intellectual content, provided comments, and edited and reviewed the final version of the article
<b>Doris-Eva Bamioú, MD, MSc, FRCP, PhD</b>	Ear Institute, University College London, UK; National Institute for Health and Care Research, University College London Hospitals Biomedical Research Centre (Deafness and Hearing Problems Theme), London, UK	Drafting/revision of the article for content, including medical writing for content; study concept or design; analysis or interpretation of data; additional contributions: the study was conceptualized by DEB, DJW, NK, and AAM. Pilot findings from the study were included in the AAM's MSc Thesis. NK prepared the first draft of this article. MP provided guidance regarding statistical analysis. All authors reviewed the article for intellectual content, provided comments, and edited and reviewed the final version of the article

## References

- Fearnley JM, Stevens JM, Rudge P. Superficial siderosis of the central nervous system. *Brain*. 1995;118(pt 4):1051-1066.
- Wilson D, Chatterjee F, Farmer SF, et al. Infratentorial superficial siderosis: classification, diagnostic criteria, and rational investigation pathway. *Ann Neurol*. 2017; 81(3):333-343. doi: 10.1002/ana.24850.
- Chan E, Sammariae Y, Banerjee G, et al. Neuropsychological and neuroimaging characteristics of classical superficial siderosis. *J Neurol*. 2021;268(11):4238-4247. doi: 10.1007/s00415-021-10548-z.
- Sydłowski SA, Levy M, Hanks WD, Clark MD, Ackley RS. Auditory profile in superficial siderosis of the central nervous system: a prospective study. *Otol Neurotol*. 2013;34(4):611-619. doi: 10.1097/MAO.0b013e3182908c5a.
- Yoo A, Jou J, Klopfenstein JD, Kattah JC. Focused neuro-otological review of superficial siderosis of the central nervous system. *Front Neurol*. 2018;9:358. doi: 10.3389/fneur.2018.00358.
- Sammariae Y, Banerjee G, Farmer S, et al. Risks associated with oral deferiprone in the treatment of infratentorial superficial siderosis. *J Neurol*. 2020;267(1):239-243. doi: 10.1007/s00415-019-09577-6.
- Kumar N. Superficial siderosis: a clinical review. *Ann Neurol*. 2021;89(6):1068-1079. doi: 10.1002/ana.26083.

8. Nguengang-Wakap S, Lambert DM, Olry A, et al. Estimating global point prevalence of rare diseases: analysis of the Orphanet database. *Eur J Hum Genet.* 2019;27:1768-1769.
9. ORPHANET. Disease: superficial siderosis 2022. Accessed May 23, 2022. orphanet/consor/cgi-bin/OC\_Exp.php?lng=EN&Expert=247245.
10. European Union. Regulation (EC) N°141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products 2000. Accessed May 23, 2022. eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:018:0001:0005:EN:PDF.
11. National Institute for Health. *Public Law 97-414 97th Congress*; 1983.
12. Offenbacher H, Fazekas F, Schmidt R, Kapeller P, Fazekas G. Superficial siderosis of the central nervous system: MRI findings and clinical significance. *Neuroradiology.* 1996;38(suppl 1):S51-S56.
13. Vernooij MW, Ikram MA, Hofman A, Krestin GP, Breteler MMB, van der Lugt A. Superficial siderosis in the general population. *Neurology.* 2009;73(3):202-205. doi: 10.1212/WNL.0b013e3181ae7c5e.
14. Pichler M, Vemuri P, Rabinstein AA, et al. Prevalence and natural history of superficial siderosis: a population-based study. *Stroke.* 2017;48(12):3210-3214. doi: 10.1161/STROKEAHA.117.018974.
15. Friedauer LR-K,B, Rezny-Kasprzak B, Steinmetz H, du Mesnil de Rochemont R, Foerch C. Spinal dural leaks in patients with infratentorial superficial siderosis of the central nervous system-refinement of a diagnostic algorithm. *Eur J Neurol.* 2022; 29(4):1136-1144. doi: 10.1111/ene.14611.
16. Vankan P. Prevalence gradients of Friedreich's ataxia and R1b haplotype in Europe co-localize, suggesting a common palaeolithic origin in the Franco-Cantabrian ice age refuge. *J Neurochem.* 2013;126(suppl 1):11-20. doi: 10.1111/jnc.12215.
17. Ruano L, Melo C, Silva MC, Coutinho P. The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. *Neuroepidemiology.* 2014;42(3):174-183. doi: 10.1159/000358801.
18. Sullivan R, Yau WY, O'Connor E, Houlden H. Spinocerebellar ataxia: an update. *J Neurol.* 2019;266(2):533-544. doi: 10.1007/s00415-018-9076-4.
19. Staquet M, Berzon R, Osoba D, Machin D. Guidelines for reporting results of quality of life assessments in clinical trials. *Qual Life Res.* 1996;5(5):496-502. doi: 10.1007/BF00540022.
20. McKenna SP. Measuring patient-reported outcomes: moving beyond misplaced common sense to hard science. *BMC Med.* 2011;9:86. doi: 10.1186/1741-7015-9-86.
21. European Organisation for Rare Disorders. *Position Paper: Patients' Priorities and Needs for RD Research 2014-2020*; 2011.
22. Benjamin K, Vernon MK, Patrick DL, Perfetto E, Nestler-Parr S, Burke L. Patient-reported outcome and observer-reported outcome assessment in rare disease clinical trials: an ISPOR COA emerging good practices task force report. *Value Health.* 2017; 20(7):838-855. doi: 10.1016/j.jval.2017.05.015.
23. Karimi M, Brazier J. Health-related quality of life, and quality of life: what is the difference? *Pharmacoeconomics.* 2016;34(7):645-649. doi: 10.1007/s40273-016-0389-9.
24. National Institute for Health and Care Excellence. *Glossary: Health-Related Quality of Life.* National Institute for Health and Care Excellence; 2021. Accessed May 23, 2022. nice.org.uk/Glossary?letter=H#Health-related%20quality%20of%20life.
25. Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-SL value set for England. *Health Econ.* 2018;27(1):7-22. doi: 10.1002/hec.3564.
26. National Institute for Health and Care Excellence. *Guide to the Methods of Technology Appraisal.* National Institute for Health and Care Excellence (NICE); 2013.
27. National Institute for Health and Care Excellence. *Centre for Health Technology Evaluation (CHTE) Methods Review 2019/2020.* NICE Task and Finish Group report; 2020.
28. Kongsved SM, Basnov M, Holm-Christensen K, Hjollund NH. Response rate and completeness of questionnaires: a randomized study of internet versus paper-and-pencil versions. *J Med Internet Res.* 2007;9(3):e25. doi: 10.2196/jmir.9.3.e25.
29. Ritter P, Lorig K, Laurent D, Matthews K. Internet versus mailed questionnaires: a randomized comparison. *J Med Internet Res.* 2004;6(3):e29. doi: 10.2196/jmir.6.3.e29.
30. Feeny D, Furlong W, Torrance GW, et al. Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. *Med Care.* 2002;40(2):113-128. doi: 10.1097/00005650-200202000-00006.
31. Grutters JPC, Joore MA, van der Horst F, Verschuure H, Dreschler WA, Anteunis LJC. Choosing between measures: comparison of EQ-5D, HUI2 and HUI3 in persons with hearing complaints. *Qual Life Res.* 2007;16(8):1439-1449. doi: 10.1007/s11136-007-9237-x.
32. EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. *Health Policy.* 1990;16(3):199-208. doi: 10.1016/0168-8510(90)90421-9.
33. Fryback DG, Palta M, Cherepanov D, Bolt D, Kim JS. Comparison of 5 health-related quality-of-life indexes using item response theory analysis. *Med Decis Making.* 2010; 30(1):5-15. doi: 10.1177/0272989X09347016.
34. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI): concepts, measurement properties and applications. *Health Qual Life Outcomes.* 2003; 1:54. doi: 10.1186/1477-7525-1-54.
35. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Qual Life Res.* 2011;20(10):1727-1736. doi: 10.1007/s11136-011-9903-x.
36. National Institute for Health and Care Excellence. *Position Statement on the Use of the EQ-5D-SL Value Set for England*; 2019. Accessed July 11, 2022 nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-sl.
37. van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. *Value Health.* 2012;15(5):708-715. doi: 10.1016/j.jval.2012.02.008.
38. Janssen MF, Szende A, Cabases J, Ramos-Goni JM, Vilagut G, Konig HH. Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. *Eur J Health Econ.* 2019;20(2):205-216. doi: 10.1007/s10198-018-0955-5.
39. Dolan P. Modeling valuations for EuroQol health states. *Med Care.* 1997;35(11):1095-1108. doi: 10.1097/00005650-199711000-00002.
40. Richardson J, Iezzi A, Khan MA. Why do multi-attribute utility instruments produce different utilities: the relative importance of the descriptive systems, scale and 'micro-utility' effects. *Qual Life Res.* 2015;24(8):2045-2053. doi: 10.1007/s11136-015-0926-6.
41. Szende A, Janssen B, Cabases J. *Self-Reported Population Health: An International Perspective Based on EQ-5D.* Dordrecht: Springer Netherlands, Imprint Springer 2014.
42. Luo N, Johnson JA, Shaw JW, Feeny D, Coons SJ. Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index. *Med Care.* 2005;43(11):1078-1086. doi: 10.1097/01.mlr.0000182493.57090.c1.
43. Feeny D, Kaplan MS, Huguet N, McFarland BH. Comparing population health in the United States and Canada. *Popul Health Metr.* 2010;8:8. doi: 10.1186/1478-7954-8-8.
44. Fisk JD, Brown MG, Sketris IS, Metz LM, Murray TJ, Stadnyk KJ. A comparison of health utility measures for the evaluation of multiple sclerosis treatments. *J Neurol Neurosurg Psychiatry.* 2005;76(1):58-63. doi: 10.1136/jnnp.2003.017897.
45. Ward Fuller G, Hernandez M, Pallot D, Lecky F, Stevenson M, Gabbe B. Health state preference weights for the glasgow outcome scale following traumatic brain injury: a systematic review and mapping study. *Value Health.* 2017;20(1):141-151. doi: 10.1016/j.jval.2016.09.2398.
46. Moore A, Young CA, Hughes DA. Mapping ALSFRS-R and ALSUI to EQ-5D in patients with motor Neuron disease. *Value Health.* 2018;21(11):1322-1329. doi: 10.1016/j.jval.2018.05.005.
47. Scott A, Jeon SH, Joyce CM, et al. A randomised trial and economic evaluation of the effect of response mode on response rate, response bias, and item non-response in a survey of doctors. *BMC Med Res Methodol.* 2011;11:126. doi: 10.1186/1471-2288-11-126.

# Neurology<sup>®</sup>

## Health-Related Quality of Life in Adults With Classical Infratentorial Superficial Siderosis: A Cross-sectional Study

Natallia Kharytaniuk, Amir Ala Mazaheri, Menelaos Pavlou, et al.  
*Neurology* 2022;99:e2201-e2211 Published Online before print August 25, 2022  
DOI 10.1212/WNL.0000000000201115

**This information is current as of August 25, 2022**

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://n.neurology.org/content/99/19/e2201.full">http://n.neurology.org/content/99/19/e2201.full</a>
<b>References</b>	This article cites 38 articles, 3 of which you can access for free at: <a href="http://n.neurology.org/content/99/19/e2201.full#ref-list-1">http://n.neurology.org/content/99/19/e2201.full#ref-list-1</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>All Neurotology</b> <a href="http://n.neurology.org/cgi/collection/all_neurotology">http://n.neurology.org/cgi/collection/all_neurotology</a> <b>Quality of life</b> <a href="http://n.neurology.org/cgi/collection/quality_of_life">http://n.neurology.org/cgi/collection/quality_of_life</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

